Triple negative breast cancer Trials in Philadelphia, United States
Conditions / Triple negative breast cancer / Philadelphia, United States
Triple negative breast cancer is a medical condition with active clinical research programs worldwide.
34 total trials for this combination
Showing top 10 of 34 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | TERMINATED | PHASE1 |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | RECRUITING | PHASE1/PHASE2 |
| NCT01677455 | An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer | COMPLETED | PHASE2 |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | TERMINATED | PHASE1 |
| NCT01391143 | Safety Study of MGA271 in Refractory Cancer | COMPLETED | PHASE1 |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | TERMINATED | PHASE1 |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | COMPLETED | PHASE1 |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | COMPLETED | PHASE1/PHASE2 |
| NCT05633654 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | RECRUITING | — |